This project was a summer completed through The Indiana University Medical Student Program for Research and Scholarship summer program.Background and Hypothesis: The TMPRSS2-ERG re-arrangement occurs in ~50% of prostate cancers and results in aberrant expression of the transcription factor ERG in the prostate. ERG is known to be activated by the Ras/ERK and PI3K/AKT pathways, however, the exact mechanism of this activation is not fully understood. The aim of this project is to identify how activation of these signaling pathways differentially effect transcription of ERG target genes. Experimental Design or Project Methods: In order to test how the Ras/ERK and PI3K/AKT pathways effect ERG target gene transcription, normal prostate...
PURPOSE: To evaluate associations between pathologic factors and erythroblast transformation-speci...
SummaryChromosomal rearrangements fusing the androgen-regulated gene TMPRSS2 to the oncogenic ETS tr...
ERG gene rearrangements are found in about one half of all prostate cancers. Functional analyses do ...
The TMPRSS2/ERG gene rearrangement occurs in 50% of prostate tumors and results in expression of the...
The TMPRSS2/ERG gene rearrangement occurs in 50% of prostate tumors and results in expression of the...
TMPRSS2–ERG is the most frequent type of genomic rearrangement present in prostate tumors, in which ...
Recently the fusion gene TMPRSS2-ERG has been highlighted as a cancer-specific event in prostate car...
The transmembrane protease serine 2:v-ets erythroblastosis virus E26 oncogene homolog (TMPRSS2:ERG) ...
The second most prevalent cancer among men with a 5-year survival rate of 30%, prostate cancer is a ...
© 2017, Spandidos Publications. All rights reserved. The oncogene ETS-related gene (ERG) encodes a t...
The ERG gene belongs to the ETS family of transcription factors and has been found to be involved in...
© 2016 Macmillan Publishers Limited All rights reserved. ETS-related gene (ERG) is a member of the E...
Approximately 50% of human prostate cancers carry a gene fusion involving the 5' untranslated region...
The discovery of recurrent gene fusions between AR-regulated transmembrane protease and ERG has shed...
In this issue of Cancer Cell, Yu and colleagues mapped the genomic binding sites of ERG and androgen...
PURPOSE: To evaluate associations between pathologic factors and erythroblast transformation-speci...
SummaryChromosomal rearrangements fusing the androgen-regulated gene TMPRSS2 to the oncogenic ETS tr...
ERG gene rearrangements are found in about one half of all prostate cancers. Functional analyses do ...
The TMPRSS2/ERG gene rearrangement occurs in 50% of prostate tumors and results in expression of the...
The TMPRSS2/ERG gene rearrangement occurs in 50% of prostate tumors and results in expression of the...
TMPRSS2–ERG is the most frequent type of genomic rearrangement present in prostate tumors, in which ...
Recently the fusion gene TMPRSS2-ERG has been highlighted as a cancer-specific event in prostate car...
The transmembrane protease serine 2:v-ets erythroblastosis virus E26 oncogene homolog (TMPRSS2:ERG) ...
The second most prevalent cancer among men with a 5-year survival rate of 30%, prostate cancer is a ...
© 2017, Spandidos Publications. All rights reserved. The oncogene ETS-related gene (ERG) encodes a t...
The ERG gene belongs to the ETS family of transcription factors and has been found to be involved in...
© 2016 Macmillan Publishers Limited All rights reserved. ETS-related gene (ERG) is a member of the E...
Approximately 50% of human prostate cancers carry a gene fusion involving the 5' untranslated region...
The discovery of recurrent gene fusions between AR-regulated transmembrane protease and ERG has shed...
In this issue of Cancer Cell, Yu and colleagues mapped the genomic binding sites of ERG and androgen...
PURPOSE: To evaluate associations between pathologic factors and erythroblast transformation-speci...
SummaryChromosomal rearrangements fusing the androgen-regulated gene TMPRSS2 to the oncogenic ETS tr...
ERG gene rearrangements are found in about one half of all prostate cancers. Functional analyses do ...